Biotechnology News and Research

RSS

Amgen, Micromet to expand development of BiTE antibodies against solid tumors

Micromet, Inc. announced today that it has entered into a collaboration agreement with Amgen Inc. for the research of BiTE antibodies against three undisclosed solid tumor targets.

11 Jul 2011

Positive top-line results from alemtuzumab Phase 3 trial on multiple sclerosis

Sanofi and its subsidiary Genzyme announced today positive top-line results from CARE-MS I, the first of two randomized, Phase 3 clinical trials comparing the investigational drug alemtuzumab to the approved multiple sclerosis therapy Rebif in patients with relapsing-remitting multiple sclerosis.

11 Jul 2011

Life Technologies introduces new India Distribution Center

Life Technologies Corporation announced today that it has launched a regional distribution hub in India to address strong customer demand in the South Asia region.

11 Jul 2011

Preliminary results from Generex Oral-lyn clinical trial on type 1 diabetes

Generex Biotechnology Corporation today announced preliminary clinical results of two major trials using the Generex Oral-lyn formulation that will be used for registration and marketing.

11 Jul 2011

QIAGEN to acquire Cellestis

QIAGEN N.V. today announced that it has amended its original proposal to acquire Cellestis Limited, a publicly traded Australian biotechnology company.

From QIAGEN Manchester Limited 11 Jul 2011

Top-line results from HyQ subcutaneous IG phase III study in patients with primary immunodeficiency

Baxter International Inc. and Halozyme Therapeutics, Inc. today announced top-line results of a phase III study of HyQ, an investigational facilitated subcutaneous immune globulin (IG) product for use in patients with primary immunodeficiency (PI).

From Baxter International Inc. 8 Jul 2011

First dog enters ADXS-HER2 dose-ranging study in canine osteosarcoma

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announces that the first dog has entered a dose-ranging in canine osteosarcoma at the University of Pennsylvania School of Veterinary Medicine.

8 Jul 2011

Corporates profit from pinkwashing

Companies that try to increase sales of their products by adopting the color pink and pink ribbons to imply that they support breast cancer research-a practice called pinkwashing-but at the same time permit the use of chemicals shown to cause cancer are committing a form of social injustice against women, according to a thought-provoking article in Environmental Justice.

8 Jul 2011

Broken compact fluorescent light bulbs can release harmful mercury vapor for a long time

Once broken, a compact fluorescent light bulb continuously releases mercury vapor into the air for weeks to months, and the total amount can exceed safe human exposure levels in a poorly ventilated room, according to study results reported in Environmental Engineering Science, a peer-reviewed online only journal published monthly by Mary Ann Liebert, Inc..

8 Jul 2011

Exenatide tQT clinical trial meets pre-specified primary endpoint

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced results from a thorough QT (tQT) study that assessed the potential of exenatide to increase the QT interval across a wide range of plasma concentrations.

8 Jul 2011

Enrollment commences in InterMune's Esbriet Phase 3 study for IPF

InterMune today announced that patient enrollment has begun in ASCEND, a new Phase 3 study of pirfenidone for patients who suffer from idiopathic pulmonary fibrosis.

8 Jul 2011

Researchers find new molecule that controls pain sensitivity from UVB irradiation

Researchers at King's College London have found a molecule in the body which controls sensitivity to pain from UVB irradiation, identifying it as a new target for medicines to treat pain caused by other common inflammatory conditions such as arthritis.

7 Jul 2011

GEN article reports on new drug research and development costs

A policy specialist and a healthcare economist both say that the oft-quoted cost of $1.32 billion to bring a new drug to market does not hold up to close scrutiny, reports Genetic Engineering & Biotechnology News.

7 Jul 2011

Low temperature vacuum drying process for production of probiotics

Probiotic bacteria are rapidly gaining ground as healthy food supplements. However, the production of this "functional food" has its pitfalls: only few probiotic bacterial strains are robust enough to survive conventional production processes.

7 Jul 2011

Toxic waste exposure impacts residents' health in Campania Region

Scientific evidence is mounting in support of a significant increase in cancer mortality and malformations occurring in specific areas of the Campania Region of Southern Italy, where improper waste management and illegal waste trafficking have been repeatedly documented, according to "Wasting lives: the effects of toxic waste exposure on health.

7 Jul 2011

Men more likely to fake soccer injuries than women

With the Women's World Cup in full swing in Germany, soccer fans can now rest assured that women are less likely than men to fake on-field injuries, according to a new study by researchers at Wake Forest Baptist Medical Center published in the July issue of the journal Research in Sports Medicine.

7 Jul 2011

FDA grants Advaxis pre-IND meeting for Advaxis-PSA immunotherapy for prostate cancer

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been granted a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration on August 10, 2011 to discuss the CMC, pharmacology, toxicology, and clinical plans for Advaxis PSA, its construct to fight prostate cancer.

1 Jul 2011

Positive topline results from Alkermes ALKS 9070 phase 1b study for schizophrenia

Alkermes, Inc. today announced positive topline results from a phase 1b, double-blind, randomized, placebo-controlled study of ALKS 9070 in patients with schizophrenia.

30 Jun 2011

Auxilium reports three year data from XIAFLEX CORDLESS study in Dupuytren's contracture

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced three year recurrence data from the Collagenase Optimal Reduction of Dupuytren's - Long-term Evaluation of Success Study (CORDLESS) for XIAFLEX® (collagenase clostridium histolyticum) in the treatment of adult Dupuytren's contracture patients with a palpable cord.

30 Jun 2011

Lotus Tissue Repair to develop DEB protein replacement therapy with $26 million Series A financing

Lotus Tissue Repair, Inc. today announced the closing of a $26 million Series A financing led by Third Rock Ventures. Proceeds of the financing will be used to advance the company's proprietary recombinant collagen type VII (rC7) technology as the first and only protein replacement therapy in development for the treatment of dystrophic epidermolysis bullosa (DEB), an orphan disease that causes devastating skin blisters, morbidity and early mortality.

30 Jun 2011